Author Archives: Marisa Wexler MS

First-in-class Blenrep Approved by European Commission for Myeloma

The European Commission (EC) has approved Blenrep (belantamab mafodotin), a first-in-class therapy developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma. The approval covers Blenrep as a monotherapy  — that is, without other treatments — in adults who have been treated with at least four…

Sarclisa Triple Combo Prolongs Life Without Disease Progression in Some Myeloma Patients, Interim Data Show

A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or refractory multiple myeloma, interim results from a Phase 3 clinical trial suggest. The findings were shared at the European Hematology Association (EHA) 2020 Virtual Congress,…

UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo

The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed or refractory multiple myeloma. This draft decision means that, at present, NICE will not…